@prefix dcterms: <http://purl.org/dc/terms/> .
@prefix this: <http://www.tkuhn.ch/bel2nanopub/RA4hsO6cHp2PIUyHdjrea2eAzpQ9YbnbTNL42bdaC3S-w> .
@prefix sub: <http://www.tkuhn.ch/bel2nanopub/RA4hsO6cHp2PIUyHdjrea2eAzpQ9YbnbTNL42bdaC3S-w#> .
@prefix beldoc: <http://resource.belframework.org/belframework/1.0/knowledge/large_corpus.bel> .
@prefix rdfs: <http://www.w3.org/2000/01/rdf-schema#> .
@prefix rdf: <http://www.w3.org/1999/02/22-rdf-syntax-ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .
@prefix dce: <http://purl.org/dc/elements/1.1/> .
@prefix pav: <http://purl.org/pav/> .
@prefix np: <http://www.nanopub.org/nschema#> .
@prefix belv: <http://www.selventa.com/vocabulary/> .
@prefix prov: <http://www.w3.org/ns/prov#> .
@prefix Protein: <http://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI_36080> .
@prefix mgi: <http://www.informatics.jax.org/marker/MGI:> .
@prefix geneProductOf: <http://purl.obolibrary.org/obo/RO_0002204> .
@prefix go: <http://amigo.geneontology.org/amigo/term/GO:> .
@prefix mesh: <http://purl.bioontology.org/ontology/MSH/> .
@prefix occursIn: <http://purl.obolibrary.org/obo/BFO_0000066> .
@prefix species: <http://www.ncbi.nlm.nih.gov/Taxonomy/Browser/wwwtax.cgi?id=> .
@prefix pubmed: <http://www.ncbi.nlm.nih.gov/pubmed/> .
@prefix orcid: <http://orcid.org/> .

sub:Head {
  this: np:hasAssertion sub:assertion;
    np:hasProvenance sub:provenance;
    np:hasPublicationInfo sub:pubinfo;
    a np:Nanopublication .
}

sub:assertion {
  sub:_1 geneProductOf: mgi:107936;
    a Protein: .
  
  sub:_2 occursIn: mesh:D005347, species:10090;
    rdf:object go:0001568;
    rdf:predicate belv:increases;
    rdf:subject sub:_1;
    a rdf:Statement .
  
  sub:assertion rdfs:label "p(MGI:Il18) -> bp(GO:\"blood vessel development\")" .
}

sub:provenance {
  beldoc: dce:description "Approximately 61,000 statements.";
    dce:rights "Copyright (c) 2011-2012, Selventa. All rights reserved.";
    dce:title "BEL Framework Large Corpus Document";
    pav:authoredBy sub:_4;
    pav:version "1.4" .
  
  sub:_3 prov:value "However, the effect of IL-18 on basal proliferation, as examined in our study, was not explored. This group also found that murine, not human, IL-18 suppressed FGF-2-induced corneal neovascularization in mice, although the IL-18 was administered by i.p. injections, and it is unclear whether local rather than systemic treatment would have induced divergent results. Interestingly, they also found that IL-18 suppressed angiogenesis in the chick chorioallantoic membrane model. Our finding that IL-18 did not induce HMVEC proliferation is consistent with results obtained for other angiogenic mediators, such as soluble VCAM-1 or soluble E-selectin, which also do not induce endothelial proliferation (14). Consistent with the chemotactic properties of IL-18, we also showed IL-18 induction of HMVEC tube formation in Matrigel matrix in vitro. The degree of tube formation by IL-18 at 1 nM was comparable with the stimulant PMA (50 mM), a potent inducer of HMVEC differentiation and tube formation (51). In the Matrigel in vivo mouse angiogenesis model, IL-18 also stimulated actual blood vessel formation, which was visibly in excess of control.";
    prov:wasQuotedFrom pubmed:11466388 .
  
  sub:_4 rdfs:label "Selventa" .
  
  sub:assertion prov:hadPrimarySource pubmed:11466388;
    prov:wasDerivedFrom beldoc:, sub:_3 .
}

sub:pubinfo {
  this: dcterms:created "2014-07-03T14:29:57.521+02:00"^^xsd:dateTime;
    pav:createdBy orcid:0000-0001-6818-334X, orcid:0000-0002-1267-0234 .
}